SCHEMBL14358697

SCHEMBL14358697

O=S(=O)(Nc1ccc(C=Cc2ccc(NS(=O)(=O)C3CC3)cc2)cc1)C1CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.49
SGK1 O00141 2/20 0.43
BRPF1 P55201 2/20 0.43
MAP2K4 P45985 2/20 0.42
HRH3 Q9Y5N1 1/20 0.41
UCHL1 P09936 1/20 0.38
USP30 Q70CQ3 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KIT P10721 1/20 0.38
BRD4 O60885 2/20 0.38
PRMT6 Q96LA8 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP17A1 P05093 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14358694 1.00 HDAC4 (0.49) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL12678579 0.90 HDAC4 (0.45) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL14358482 0.87 CA1 (0.49) HDAC4PTGS1KMT2A
SCHEMBL14358479 0.87 CA1 (0.49) HDAC4PTGS1KMT2A
SCHEMBL21933263 0.83 EPHX2 (0.52) HDAC4
SCHEMBL3980159 0.78 CA1 (0.53) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL28207342 0.78 HDAC4 (0.47) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL21590270 0.78 CA1 (0.53) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL3088517 0.78 SGK1 (0.51) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL14830078 0.78 MAP2K4 (0.56) HDAC4SGK1BRPF1MAP2K4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP claimed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US claimed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO claimed
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (US) 2019-02-19 US disclosed
EP-2724156-B1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE JACKSON LAB (US) 2017-08-16 EP disclosed
EP-2724156-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE The Jackson Laboratory (US) 2014-04-30 EP disclosed
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-07-18 US disclosed
WO-2013003112-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE THE JACKSON LABORATORY (US) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184342-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE BAK1, SSB, MRE11 HDAC4 542/4885SGK1 518/4885BRPF1 1428/4885
US-10207988-B2 Methods and compositions for treatment of cancer and autoimmune disease BAK1, SSB, MRE11 HDAC4 542/4885SGK1 518/4885BRPF1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.